Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

284039

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma of the anal canal (SCAC), a rare cancer of the digestive system, in adults who are unable to receive, or whose disease progressed after, initial platinum-based chemotherapy. Incyte’s biologics licence application (BLA) to the U.S. Food and Drug Administration (FDA) was granted priority review status, which is expected to shorten the regulatory review from the standard 10 months to six…

You must be logged in to read/download the full post.